Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK120 in Moderate to Severe Atopic Dermatitis
NCT06035354Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of manfidokimab in atopic dermatitis (AD) (7 arms), sponsored by Akeso, Inc. Primary endpoints: Incidence of treatment-emergent adverse events at Week 16, Pharmacokinetics of AK120 at Week 12 and 1 more. Started Nov 2021; status: completed.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06035354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035354.